Transitional Cell Carcinoma of the Urinary Bladder Following Exposure to Cyclophosphamide in Childhood

Summary

With the increasing survival of children with malignancies, the long-term effects of chemotherapies are now becoming important and one of these dreadful long-term complications is the development of a second malignancy. Described here is a case of transitional cell carcinoma of the bladder developing 8 years following exposure to cyclophosphamide for the treatment of embryonal rhabdomyosarcoma.

Résumé

Avec l'augmentation de la survie des enfants traités pour tumeurs malignes, les effets à long terme de la chimiothérapie deviennent maintenant plus importants et l'une de ces complications à long terme est le développement d'une seconde tumeur maligne. L'auteur décrit le cas d'un carcinome de la vessie développé 8 ans après un traitement par cyclophosphamide pour rhabdomyosarcome embryonnaire.

Resumen

Con el incremento de supervivencia de niños con tumores malignos los efectos de los quimioterápicos a largo plazo empiezan a ser importantes y una de estas complicaciones es el desarrollo de segundos tumores. Describimos un caso de carcinoma de células transicionales de la vejiga que se desarrolló 8 años después de la exposición a ciclofosfamida para el tratamiento de un rabdomiosarcoma embrionario.

Zusammenfassung

Mit der zunehmenden Zahl von Kindern, die maligne Tumoren überleben, steigt die Bedeutung der Nebenwirkungen einer Chemotherapie. Eine dieser besonders problematischen Komplikationen ist die Entstehung von Zweittumoren. In der vorliegenden Kasuistik wird die Entwicklung eines „Transitional cell carcinoms“ der Blase beschrieben, welches 8 Jahre nach der Behandlung des Kindes mit Cyclophosphamid wegen eines embryonalen Rhabdomyosarkoms entstanden ist.

Key words

Second malignancy - Cyclophosphamide - Transitional cell carcinoma

Mots-clés

Deuxième tumeur maligne - Cyclophophamide - Carcinome

Palabras clave

Segundo tumor - Ciclofosfamida - Carcinoma de células transicionales

Schlüsselwörter

Maligner Zweittumor - Cyclophosphamid - embryonales Rhabdomyosarkom der Blase - Transitional cell carcinoma

References

• 1 Aptekar R G, Sailsbury K W, Steinberg A D, Myers G H. Cyclophosphamide-induced non-hemorrhagic cystitis with abnormal bladder cells.  Arth Rheum. 1972;  15 530
• 2 Benson R C, Tomera K M, Kelalis P P. Transitional cell carcinoma of the bladder in children and adolescents.  J Urol. 1983;  130 54-55
• 3 Cox P J. Cyclophosphamide cystitis and bladder cancer: a hypothesis.  Eur J Cancer. 1979;  15 1071
• 4 Durkec C, Benson R. Bladder cancer following administration of cyclophosphamide.  Urology. 1980;  16 145
• 5 Einhorn N. Acute leukemia after chemotherapy (melphalan).  Cancer. 1978;  41 444-447
• 6 Green D M, Zevon M A, Reese P A. et al . Second malignant tumours following treatment during childhood and adolescence for cancer.  Med Ped Oncol. 1994;  22 1-10
• 7 Haddow A. The growth inhibitory and carcinogenic properties of 4-aminostilbene and derivatives.  Philosophical transections of the Royal Society of London. 1948;  Series A, 241 247
• 8 Hochberg M C, Shulman L E. Acute leukemia following cyclophosphamide therapy for Sjogren's syndrome.  Johns Hopkins Med J. 1978;  142 211-214
• 9 Hoenig D M, Mc Raes S, Chyan Chen S, Diamond D A. et al . Transitional cell carcinoma of the bladder in the pediatric patients.  J Urol. 1996;  156 203-205
• 10 Javadbowi N, Mostofi F K. Primary epithelial tumours of the bladder in the first two decades of life.  J Urol. 1969;  101 706
• 11 Kaldor J M, Day N E, Kittelmann B, Petlerson F, Langmark F, Pedersen D. et al . Bladder tumors following chemotherapy and radiotherapy for ovarian cancer: a case-control study.  Int J Cancer. 1995;  63 1-6
• 12 Kinlen L J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment.  Am J Med. 1985;  78 44-49
• 13 Levine L A, Richie J P. Urological complications of cyclophosphamide.  J Urol. 1989;  141 1063
• 14 Meadow A T, Baum E, Fossati-Bellani F, Green D, Jenkin R D, Marsden B. et al . Second malignant neoplasms in children: an update from the late effect study group.  J Clin Oncol. 1985;  3 532-538
• 15 Negalia J P. Late effects of treatment of children with cancer.  Semin Pediatr Surg. 1993;  2 29-36
• 16 Pedersen-Bjergaard J, Ersboll J, Hansen V L, Sorensen B L, Christoffersen K, Hov-Jansen K. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma.  N Engl J Med. 1988;  318 1028-1032
• 17 Pedersen-Bjergaard J. Incidence, previous treatment and chromosome characteristics of secondary acute non-lymphocytic leukemia.  Cancer Treatment Reviews. 1985;  12 65-75
• 18 Plotz P H, Klippel J H, Decker J L, Grauman D, Wolff B, Brown B C. et al . Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis.  Ann Intern Med. 1979;  91 221
• 19 Rich D C, Corpron C A, Smith M B, Black T, Lally K P, Andrassy R J. Second malignant neoplasms in children after treatment of soft tissue sarcoma.  J Pediatr Surg. 1997;  32 369-372
• 20 Robinson L L, Mertens A. Second tumours after treatment of childhood malignancies.  Hematol Oncol Clin North Am. 1993;  7 401-415
• 21 Rosner F, Grunwald H. Hodgkin's disease and acute leukemia. A report of 8 cases and review of literature.  Am J Med. 1975;  58 339-353
• 22 Rosner F, Grunwald H. Multiple myeloma terminating in acute leukemia. Report of 12 cases and review of literature.  Am J Med. 1974;  57 927-939
• 23 Scher H I, Shipley W U, Herr H W. Cancer of the bladder. DeVita VT, Hellman S, Rosenberg SA Cancer: Principles and Practice of Oncology. 5th edition. Philadelphia, New York; Lippincott-Raven 1997: 1300-1322
• 24 Schmahl D, Habs M, Lorenz M, Wagner L. Occurrence of second tumours in man after anticancer treatment.  Cancer Treat Rev. 1982;  9 167-194
• 25 Schmahl D, Habs M R. Prevention of cyclophosphamide-induced carcinogenesis in the urinary bladder of rats by administration of mesna.  Cancer Treat Rev. 1983;  10 (Suppl) 57
• 26 Seidenfeld A M, Smythe H A, Ogryzl M A, Vorwitz M B, Dotten D A. et al . Acute leukemia in rheumatoid arthritis treated with cytotoxic agents.  J Rheumatol. 1984;  11 586-587
• 27 Stillwell T J, Benson R C. Cyclophosphamide-induced hemorrhagic cystitis - a review of 100 patients.  Cancer. 1988;  61 451
• 28 Thrasher J B, Miller G J, Wettlaufer J N. Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis.  J Urol. 1990;  143 119
• 29 Travis L B, Curtis R E, Glimelius B, Holowaty E J, Van-Leeuwon F E, Lynch C F. et al . Bladder and kidney cancer following cyclophosphamide therapy for NHL.  J Natl Cancer Inst. 1995;  87 524-530
• 30 Tucker M A, Meadows A T, Boice J D, Hoover R N, Fraumeni J F. Cancer risk following treatment of childhood cancer. Boice JD, Fraumeni Jr JF Radiation Carcinogenesis: Epidemiology and Biological Significance. New York; Raven 1984: 211
• 31 Wall R L, Clausen K P. Carcinoma of the urinary bladder in patients receiving cyclophosphamide. Letter to editor.  New Engl J Med. 1981;  293 271
• 32 Worth P H. Cyclophosphamide and the bladder.  Br Med J. 1971;  3 182